Biogen Inc.

Location

Massachusetts

Founded

1978-02-28

Website

https://www.biogen.com

Risk Signals

6609 news mentions monitored

Industry Context

This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.

Filter risk signals by topic

Select a theme below to explore the company’s news mentions in specific risk areas.

US-China Diplomatic Relations (36) EU Political Updates (9) Stock Market Events (5) Corporate Rebranding (4) Cryptocurrency Market Analysis (4) Legal Proceedings (3) Research and Development (3) Corporate Insolvency (3) Inter-Organizational Collaborations (2) Corporate Relocations (2) Investment Strategies (2) Government Affairs (1) Business Growth Initiatives (1) Business Launches (1) Competitive Market Dynamics (1) Funding Announcements (1) Global Diplomacy and Conflicts (1) Antitrust and Regulatory Actions (1) Public Health Crisis Response (1) Regulatory Decisions (1) Research Breakthroughs (1) United States Political Events (1)

Recent Articles about Biogen Inc.

Live alerts from global media, monitored by Business Radar

2025-01-23 (pharmaphorum.com)

US/EU regulators start review of Biogen's high-dose Spinraza |

Biogen's new high-dose version of SMA drug Spinraza has started regulatory reviews, but can it help return the drug to growth?

2024-11-15 (dpa-international.com)

EU regulator reverses decision to block Alzheimer's drug lecanemab

The European Union's drugs regulator reversed its decision to block the Alzheimer's drug lecanemab, a treatment aimed at slowing cognitive decline in patients.

2024-11-15 (devdiscourse.com)

EU Backs Leqembi: A Breakthrough in Alzheimer's Treatment

The European Union's drugs regulator has recommended approval for Eisai and Biogen's Alzheimer's drug Leqembi. This marks a potential first treatment approval in the EU for early Alzheimer's, focusing on patients without the ApoE4 gene variant.

2024-11-15 (thehindu.com)

EU regulator backs Eisai-Biogen Alzheimer’s drug

EU drugs regulator recommends approval of Leqembi for early Alzheimer's, pending European Commission acceptance, for specific patient group.

2024-03-22 (reuters.com)

EU regulator delays decision on Eisai-Biogen Alzheimer's drug |

The European Union's medicines regulator has delayed its decision on Eisai and partner Biogen's Alzheimer's disease drug that was expected this week, the Japanese company said on Friday.

2023-08-05 (localnews8.com)

The FDA approves the first pill for postpartum depression in the US.

Sol Amaya (CNN) — The US Food and Drug Administration (FDA) has approved the drug zuranolone for the treatment of postpartum depression, making it the first FDA-approved oral pill in the United States specifically for postpartum depression, a